BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
SKBBY upcoming catalysts
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.: 5 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (3 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 3 readout(s) and 0 FDA event(s). Subscribe to SKBBY (.ics).
Drugs: SKB264, Pembrolizumab, pemetrexed, carboplatin, Docetaxel, Eribulin, Capecitabine, Gemcitabine, Vinorelbine, Cisplatin
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No upcoming PDUFA date or AdCom found. | |||||
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-30 est. | P3 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT06968585 A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab | HER2-positive Breast Cancer | active not recruiting | 365 |
| 2026-12 est. | P3 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT06711900 A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients Wi | Non-Small Cell Lung Cancer | active not recruiting | 432 |
| 2026-12-30 est. | P2 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT05631262 SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors | Selected Subjects With Advanced Solid Tumors | active not recruiting | 321 |
| 2026-12-31 est. | P1/P2 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT05265091 A Study of KL590586 in Patients With Advanced Solid Tumors | Advanced Solid Tumor | active not recruiting | 414 |
| 2026-12-31 est. | P3 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT06081959 Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer | Metastatic Breast Cancer | recruiting | 376 |
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No FDA decision events in this window. | |||||
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P3 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT06448312 A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | active not recruiting | 406 |
| 2026-08 est. | P2 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT05351788 SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer. | Non-small Cell Lung Cancer | recruiting | 110 |
| 2026-07-31 | P2 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT05445908 SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer | Triple-negative Breast Cancer and HR+/HER2- BC | completed | 184 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.